Clinigen Group plc (78C.F)
Clinigen Group plc
Pitcairn House
Crown Square Centrum 100
Burton upon Trent DE14 2WW
United Kingdom
44 1283 495 010
https://www.clinigengroup.com
Sector(s):
Industry:
Full-time employees:
Key executives
| Name | Title | Pay | Exercised | Year born |
|---|---|---|---|---|
| Richard J. Paling | Director, Interim CFO & Group Financial Controller | N/A | N/A | 1970 |
| Mr. Samuel Gordon Herbert | Chief Operating Officer | N/A | N/A | N/A |
| Rob Fox | Vice President of Investor Relations & Corporate Development | N/A | N/A | N/A |
| Ms. Amanda Miller | General Counsel | N/A | N/A | N/A |
| Jessica Archer | Global Human Resources Director | N/A | N/A | N/A |
| Mr. Mark Corbett | Managing Director of Global Access Division | N/A | N/A | N/A |
| Mr. Johannes Willemse | Chief Commercial Officer | N/A | N/A | 1968 |
| Mr. Ivo Timmermans M.D., MBA | Chief Medial Officer | N/A | N/A | 1960 |
| Mr. Terry Walsh | Senior Vice President of Clinical Trial Services | N/A | N/A | N/A |
| Mr. James Winterman | Senior Vice President of Unlicensed Medicines | N/A | N/A | N/A |
Description
Clinigen Limited provides pharmaceutical products and services. The company offers niche and high value services to pharma and biotech clients prior to product launch. It also provides access to critical medicines around the world for patients with unmet needs. In addition, the company provides a portfolio of specialist medicines to service the needs of healthcare professionals and their patients in both licensed and unlicensed markets. Further, it offers Nortriptyline Colonis for the treatment of depressive disorder; Metformin Colonis for the treatment of type 2 diabetes mellitus; Magnesium Chewable Tablets, an oral magnesium supplements for the treatment of patients with chronic magnesium loss; Iloprost, a concentrate for solution for infusion; Glycopyrronium Bromide, an oral solution for the treatment of severe sialorrhoea; Acetylcysteine, an oral solution for the treatment of respiratory disorders associated with thick, viscous, and mucus hypersecretion; Cardioxane that protects the heart against the cardiotoxic effects of anthracyclines; Ethyol, which protect against the harmful effects of chemotherapy medications and radiation treatment; Proleukin for the treatment of kidney cancer; Imukin that is used in chronic granulomatous disease; Totect, a dexrazoxane product; Foscavir, an anti-virals that work by stopping viruses from multiplying in number; and Savene, which is indicated in adults for the treatment of anthracycline extravasation. The company operates in United Kingdom, rest of Europe, the United States, South Africa, Australia, and internationally. Clinigen Limited was formerly known as Clinigen Group plc and changed its name to Clinigen Limited in May 2022. The company was incorporated in 2008 and is headquartered in Burton upon Trent, United Kingdom. Clinigen Limited operates as a subsidiary of Triley Holdco Limited.
Corporate governance
Clinigen Group plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.
